The objective of the clinical trial was to demonstrate that Metabolaid® can help reduce body fat mass, and ultimately body weight, in overweight subjects in absence of a controlled diet. The study was performed during 12 weeks, and resulted in a significant reduction in body weight, body mass index, and fat mass, with no loss of lean nor water mass. Body fat mass was measured using the DEXA scan, which is the gold-standard in body compartment assessment. The abdominal region was where the most significant body fat loss was observed.
Read all about this clinical trial by clicking this link: https://www.mdpi.com/2304-8158/9/1/55
Related Articles:
https://www.monteloeder.com/blog/2019/10/metabolaid-seminar-in-taiwan/
https://www.monteloeder.com/blog/2019/11/digital-solutions-to-fight-against-obesity/
https://www.monteloeder.com/blog/2018/12/hibiscus-and-lemon-verbena-polyphenols-modulate-appetite-related-biomarkers-in-overweight-subjects-a-randomized-controlled-trial/
